Results 261 to 270 of about 252,165 (283)
Some of the next articles are maybe not open access.
Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
CLL-283: CLL-Derived Exosomes Turn Endothelial Cells into CLL-Supportive Cells
Clinical Lymphoma Myeloma and Leukemia, 2021We hypothesized that via exosomes, CLL cells turn endothelial cells into “CLL-supportive cells.” To test this hypothesis, we transfected vein-derived (HUVECs) and arterial-derived (HAOEC) endothelial cells with exosomes that we isolated from the peripheral blood of 45 treatment-naive patients.
Uri Rozovski +11 more
openaire +1 more source
2013
Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy.
Jae H, Park, Renier J, Brentjens
openaire +2 more sources
Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy.
Jae H, Park, Renier J, Brentjens
openaire +2 more sources
Blood, 2013
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).
openaire +2 more sources
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).
openaire +2 more sources
Hematology, 2005
AbstractChronic lymphocytic leukemia (CLL) follows an extremely variable course with survival ranging from months to decades. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in CLL patients.
openaire +2 more sources
AbstractChronic lymphocytic leukemia (CLL) follows an extremely variable course with survival ranging from months to decades. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in CLL patients.
openaire +2 more sources
Hematology, 2008
Abstract Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous clinical course, with some patients requiring immediate therapy and others living without need for treatment for decades. There has been considerable interest in the underlying molecular mechanisms of this heterogeneity to understand not only the expected clinical
openaire +2 more sources
Abstract Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous clinical course, with some patients requiring immediate therapy and others living without need for treatment for decades. There has been considerable interest in the underlying molecular mechanisms of this heterogeneity to understand not only the expected clinical
openaire +2 more sources
Blood, 2010
Elevated plasma levels of the angiogenic factor Ang-2 correlated with poor prognosis in a larger series of CLL patients. Ang-2 levels may reflect crosstalk between CLL cells and their microenvironment, specifically related to angiogenesis and endothelial cells, and therefore emphasize the importance of angiogenesis in CLL. .
openaire +2 more sources
Elevated plasma levels of the angiogenic factor Ang-2 correlated with poor prognosis in a larger series of CLL patients. Ang-2 levels may reflect crosstalk between CLL cells and their microenvironment, specifically related to angiogenesis and endothelial cells, and therefore emphasize the importance of angiogenesis in CLL. .
openaire +2 more sources
Poster: CLL-283: CLL-Derived Exosomes Turn Endothelial Cells into CLL-Supportive Cells
Clinical Lymphoma Myeloma and Leukemia, 2021Uri Rozovski +11 more
openaire +1 more source